Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2962 phase I/II study in relapsed or refractory MDS and dysplastic CMML
jRCT2031250235Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of azd2962 in hematopoietic malignancies, myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by AstraZeneca. Primary endpoints: Dose-limiting toxicities, Adverse events and serious adverse events and 2 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
azd2962
03
Conditions
hematopoietic malignanciesmyelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on jRCT2031250235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250235.